Search Within
Document Type
112-35-6
Applied Filters:
Keyword:'112-35-6'
Showing 1-30 of 283 results for "112-35-6" within Technical Documents
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
2360 38 41 43 161 35
28 19 26 22 114 56 34 123 24 2339 33 40 40 165 33
std
6
27 16 24 20 111 56 35 112 22 5265 35 40 38 150
Data Sheet -NovaSeptum® SURe
–80 to 125 °C
(–112 to 257 °F)
C-Flex® designs –80 (when used with a
NovaSeptum® Case) to
50 °C (–112 to 122 °F)
–80 to 50 °C
(–112 to 122 °F)**
2
Data Sheet - I1907
95, 11211-11216 (1998).
5. Tu, Y., et al., Mol. Cell. Biol., 19, 2425-2434 (1999).
6. Wu, C., J. Cell Sci., 112, 4485-4489 (1999).
7. Wu, C., et al., J. Biol. Chem., 273, 528-536 (1998).
8. Radeva
Quality Control Ranges: MILLIPLEX® MAP Mouse High Sensitivity T Cell Magnetic Bead Panel
Control 1 211 – 438 pg/mL IL-10 Control 1 54 – 112 pg/mL
Control 2 813 – 1688 pg/mL Control 2 212 – 441 pg/mL
Influence of Environmental Sample Pre-Storage on Counting Results
inoculation
and then incubated at 30 °C to 35 °C
4. The sample is stored at 4 °C to 8 °C for 6
hours after surface sampling or inoculation
and then incubated at 30 °C to 35 °C
Product Information Sheet - I1907
95, 11211-11216 (1998).
5. Tu, Y., et al., Mol. Cell. Biol., 19, 2425-2434 (1999).
6. Wu, C., J. Cell Sci., 112, 4485-4489 (1999).
7. Wu, C., et al., J. Biol. Chem., 273, 528-536 (1998).
8. Radeva
Nitrite Spectroquant Test Kits Equivalency Report 2017
.135
Matrix Spike Percent Recovery 112 % 112%
Matrix Spike Duplicate
(NO2-N mg/L))
0.138 0.135
Matrix Spike Duplicate Percent
Recovery 108 % 112 %
Relative Percent Difference 3.00
LABORATORY NOTEBOOK ISSUANCE PAGE
.9
74
32
.0
6
35
.4
5
39
.9
48
69
.7
23
72
.6
3
74
.9
22
78
.9
6
79
.9
04
83
.7
98
11
4.
82
11
8.
71
12
1.
76
12
Product Information Sheet - B4750
369-374 (1980).
6. Kopitar, M., et al., Cerebrocystatin suppresses
degradation of myelin basic protein by purified
brain cysteine proteinase. Biochem. Biophys.
Res. Commun., 112(3), 1000-1006 (1983
The Effective Use of Protein Kinase Inhibitors
38 81 104 118 86 86 88 99 83 37 104 104 105 2 21 9
PRAK 81 104 91 6 36 93 71 108 112 88 85 68 51 74 76 104 96 98 89
PKA 2
Data Sheet - SAB4200247
packing slip.
6. Clemetson, K.J., Thromb. Haemost., 98, 63-68
(2007).
7. Li, S., et al., J. Thromb. Haemost., 8, 341-350
(2010).
8. Ramasamy, I., Crit. Rev. Oncol. Hematol., 49, 1-35
(2004).
LABORATORY NOTEBOOK ISSUANCE PAGE
.9
74
32
.0
6
35
.4
5
39
.9
48
69
.7
23
72
.6
3
74
.9
22
78
.9
6
79
.9
04
83
.7
98
11
4.
82
11
8.
71
12
1.
76
12
LABORATORY NOTEBOOK ISSUANCE PAGE
.9
74
32
.0
6
35
.4
5
39
.9
48
69
.7
23
72
.6
3
74
.9
22
78
.9
6
79
.9
04
83
.7
98
11
4.
82
11
8.
71
12
1.
76
12
Data Sheet - 51463
Rustigian, C.A. Stuart, Decomposition of urea by Proteus, Proc. Soc. Exptl. Biol. Med., 47, 108-
112 (1941)
2. C.A. Stuart, E. Van Stratum, R. Rustigian, Further studies on urease production by Proteus
114815 - Spectroquant Calcium Test
10 1.0 - 15.0 1.4 - 21.0 2.5 - 37.5
10 10 - 160 14 - 224 25 - 400 100
20 5 - 80 7 - 112 12 - 200
Data Sheet - P1115
(1989).
6. Brown, D. R., Trends Neurosci., 24, 85-90 (2001).
7. Kretzschmar, H. A. et al., Arch. Virol. Suppl., 16,
239-249 (2000).
8. Rezaie, P. and Lantos, P. L., Brain Res. Rev., 35,
55-72
Product Information Sheet - A5479
decant or pipette the supernatant from the pellet.
6. For this example the protein of interest remains in
the supernatant from step 5 (35% saturation) and a
second precipitation step at 70% saturation
Verfication summary-03-0202-00
3.2 6% 99.61 6.4 6% -
3 1:4 28.51 1.0 3% 114.04 4.0 3% 114%
3 1:8 14.85 0.2 1% 118.80 1.5 1% 119%
3 1:16 6.97 0.7 10% 111.53 10.9 10% 112%
BRH1451736
3 MRD
Verfication summary-03-0202-00
3.2 6% 99.61 6.4 6% -
3 1:4 28.51 1.0 3% 114.04 4.0 3% 114%
3 1:8 14.85 0.2 1% 118.80 1.5 1% 119%
3 1:16 6.97 0.7 10% 111.53 10.9 10% 112%
BRH1451736
3 MRD
Product Information Sheet - L9640
tetragonolobus 35 1 − galNAc, gal
Ptilota plumosa 65; 170 − B α-gal
Ricinus communis
Toxin, RCA60 60 2 − galNAc, β-gal
Toxin, RCA120 120 4 − β-gal
Sambucus nigra 140 4(αβ) − αNeuNAC(2→6)gal +c
galNAc
Product Information Sheet - L5266
Narcissus pseudonarcissus 26 2 (h) α-D-man
Perseau americana − − − −
Phaseolus coccineus 112 4 − −
Phaseolus limensis 247(II) 8 A galNAc
Product Information Sheet - L4895
Narcissus pseudonarcissus 26 2 (h) α-D-man
Perseau americana − − − −
Phaseolus coccineus 112 4 − −
Phaseolus limensis 247(II) 8 A galNAc
Milliflex Oasis Contamination Study Whitepaper
surface with the respective
disinfectant.
• Filter 100 mL of a Fluid A solution contaminated with
112 to 26000 CFUs using a funnel without membrane
in order to contaminate the fluid path. Table 2
presents
The Effective Use of Protein Kinase Inhibitors
38 81 104 118 86 86 88 99 83 37 104 104 105 2 21 9
PRAK 81 104 91 6 36 93 71 108 112 88 85 68 51 74 76 104 96 98 89
PKA 2
Product Information Sheet - L3892
Narcissus pseudonarcissus 26 2 (h) α-D-man
Perseau americana − − − −
Phaseolus coccineus 112 4 − −
Phaseolus limensis 247(II) 8 A galNAc
Product Information Sheet - L7017
Narcissus pseudonarcissus 26 2 (h) α-D-man
Perseau americana − − − −
Phaseolus coccineus 112 4 − −
Phaseolus limensis 247(II) 8 A galNAc
Product Information Sheet - L6257
MW (kDa) Subunits Blood Group Sugar Activity
Perseau americana − − − −
Phaseolus coccineus 112 4 − −
Phaseolus limensis 247(II) 8 A galNAc
Product Information Sheet - T7402
, M.M., and Tucker, J.B., J. Cell Science,
97, 101, 1990.
25. Verde, F. et al., J. Cell Biol., 112, 1177, 1991.
26. Scialli, A.R. et al., Teratogenesis, Carcinog.
Mutagen., 14, 23, 1994.
27. Adler
Product Information Sheet - L1394
Narcissus pseudonarcissus 26 2 (h) -D-man
Perseau americana
Phaseolus coccineus 112 4
Phaseolus limensis 247(II) 8
Product Information Sheet - T1912
, M.M., and Tucker, J.B., J. Cell Science,
97, 101, 1990.
25. Verde, F. et al., J. Cell Biol., 112, 1177, 1991.
26. Scialli, A.R. et al., Teratogenesis, Carcinog.
Mutagen., 14, 23, 1994.
27. Adler
Page 1 of 10